Genedata Launches Platform-Native ELN for Biopharma R&D
Basel – October 29, 2026 -- Genedata, a Danaher company, launched an electronic lab notebook (ELN) built natively into its biopharma R&D software platform, replacing standalone notebook tools with a single scientific record spanning discovery and development.
Genedata embeds the ELN in its existing platform data model
The ELN links directly to molecules, samples, process parameters, and assay and analytics results already managed in the platform. This cuts manual data transfers and inconsistencies between applications. It supports workflows for biologics and complex modalities including ADCs, bispecifics, cell and gene therapies, and peptides.
Experiment documentation stays tied to a candidate's full development history. That history runs from design and molecular biology through screening, engineering, expression, purification, and analytics to upstream and downstream process development, formulation, and analytical development.